Global Botulinum Toxin Market Size, Share & Trends Analysis Report By Product Type (Type A, Type B), By Application (Therapeutic, Aesthetic), By End-use (Dermatology Clinics, Cosmetic Centers & Medspas), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global botulinum toxin market size was exhibited at USD 11.30 billion in 2023 and is projected to hit around USD 29.04 billion by 2033, growing at a CAGR of 9.9% during the forecast period of 2024 to 2033.

Botulinum Toxin Market Size 2024 To 2033

Key Takeaways:

  • North America accounted for a significant revenue share of 47.0% in 2023
  • The Cosmetic centers and medspas accounted for the largest market share of 44.5% in 2023.
  • The botulinum toxin-type- A segment exhibited the largest revenue share of 98.8% in 2023.
  • The aesthetic segment is expected to witness a significant CAGR of 10.2% during the forecast period.

Botulinum Toxin Market Report Scope

 Report Coverage  Details
Market Size in 2024 USD 11.30 Billion
Market Size by 2033 USD 29.04 Billion
Growth Rate From 2024 to 2033 CAGR of 9.9%
Base Year 2023
Forecast Period 2024-2033
Segments Covered Product, Application, End-use, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Ipsen Group; Allergen Inc.; Medy-Tox, Inc.; Merz Pharma; US Worldmeds; Evolus; Galderma; Metabiologics Inc.; Lanzhou Institute of Biological Products.

 

The toxin is a selective blocker of acetylcholine released from nerves, which blocks neural transmission from the nerves when injected into muscle. Botulinum toxin is one of the most exceptional substances encountered in medicine and science. The adoption of botulinum toxin in cosmetology has grown rapidly over the decade, and at present it is one of the most common and widely performed aesthetic procedures in the world. The increasing concern for aesthetic features in developed and developing regions has led to an increase in the number of cosmetic procedures.

The availability of a variety of botulinum toxin products such as botox, xeomin, dysport, and others will accelerate the market growth. The increasing usage of botulinum toxin injection in several aesthetic procedures including the treatment of glabellar lines, chemical browlift, forehead lines, and others is expected to boost the botulinum toxin industry growth over the coming years. Presently, a few products of botulinum toxin - Type-A and only one product of Type-B (Myobloc) are commercially available in the market.

However, rising investment in R&D programs by major manufactures to explore the therapeutic use of botulinum toxin is building opportunities for the expansion of its therapeutic application area in the near future. A shift from invasive to minimally invasive procedures is expected to fuel the market growth over the forecast period. For instance, according to ISAPS, 17,598,888 noninvasive procedures were performed globally in 2021, out of which 5,355,604 were performed in the U.S. A large number of people are opting for permanent procedures, such as fillers, fat grafting, and lip advancement.

Minimally invasive procedures offer advantages such as smaller incisions, shorter hospital stays, quick outpatient services, rapid wound healing, lesser pain, and lower risk of complications than invasive surgeries. Thus, the demand for botulinum toxin is expected to increase over the forecast period. Moreover, many dermatologists believe that COVID-19 may act as a springboard that will drastically increase patient footfall post-pandemic.

According to a survey conducted on 1,000 American women in 2020 by American Society of Plastic Surgeons, 11% of participants indicated that they are more inclined to opt for minimally invasive procedures post-pandemic than pre-COVID-19. Even during the pandemic, Botox and soft tissue fillers remained the most popular minimally invasive procedures in the U.S.

Segments Insights:

End-use Insights

Based on end-use, the market is segmented into hospitals, dermatology clinics, and spas & cosmetic clinics. Cosmetic centers and medspas accounted for the largest market share of 45.0% in 2023. The higher preference for aesthetic procedures in dermatology clinics and cosmetic centers and medspas is significantly contributing to the segmental growth. The segment is likely to grow with a CAGR of 10.2%. Plastic surgeons and medical spa owners are seeing an increase in customers. In addition, the rising number of medical cosmetic centers and medspas in regions like Asia Pacific are contributing to the market growth.

Botulinum Toxin Market Share, By End-use, 2023 (%)

The hospital segment accounted for a revenue share of 43.4% in 2023. Rising number of hospitals with advanced care and facilities in developed and developing countries and increasing awareness for aesthetic procedures performed attributes the segment growth. Furthermore, maximum number of therapeutic procedures such as dystonia, spasticity, chronic migraine and others are being performed in the hospitals.

Product Type Insights

The botulinum toxin-type- A segment exhibited the largest revenue share of 98.8% in 2023. Botulinum toxin A is anticipated to grow at a significant rate due to rise in customer preference owing to advantages including minimal pain, no blood loss, and lack of scarring during the procedure. Botulinum toxin type-A has been increasingly utilized to treat chronic migraine, tension-type headache, and other primary neurological disorders.

Botulinum toxin-type- A products are adopted for range of therapeutic and aesthetic applications, and with the rising demand for aesthetic beauty, the segment is likely to grow further in the near future. Based on product, the botulinum toxin sector is classified into botulinum toxin type-A and botulinum toxin type-B. Also, various botulinum toxin type-A products are commercially available in the market including Botox and Dysport have been clinically tested proven to be safe and effective in long-terms with least side effects.

Application Insights

Based on application, botulinum toxin sector is segmented into aesthetic and therapeutic applications. The aesthetic segment is expected to witness a significant CAGR of 10.2% during the forecast period. Botulinum toxin (BoNT), a bacterially produced neurotoxin, is a mainstay in the cosmetology armamentarium. The rising consciousness for aesthetic appearance and rising technological advancements in developed and developing countries has led to an increase in the number of cosmetic surgeries.

The therapeutic application segment accounted for 43.0% of the market share. Botulinum toxin is known to be the most potent known biological neurotoxin molecule, and holds great promise in the treatment of many disorders. The therapeutic benefits of botulinum toxin have been diversifying due to deeper understanding of its different mechanisms of action and molecular behavior. Botox procedures are adopted for various therapeutic and preventive treatments for disorders such as chronic migraine, conditions such as hyperhidrosis, over-reactive bladders, and others.

Regional Insights

North America accounted for a significant revenue share of 47.0% in 2023 and is anticipated to reach USD 5.1 billion by 2033 owing to increasing disposable income and growing number of cosmetic procedures. For instance, in 2019, as per the American Society of Plastic Surgeons (ASPS), 1.3 million surgeries were performed with botulinum toxin products. Thus, increasing use of botulinum toxin products in various cosmetic procedures performed in the region will stimulate the North America botulinum toxin industry growth.

Botulinum Toxin Market Share, By Region 2023 (%)

The Asia-Pacific region is expected to witness the highest CAGR of 11.1% over the forecast period owing to a favorable reimbursement, large patient population, and availability of developed healthcare facilities in many countries. In countries, like South Korea, China, and Japan, there is higher beauty consciousness and aesthetic awareness, hence likely to drive the market growth. Furthermore, there is rising number of medical spas and cosmetic centers in countries like Thailand, Singapore, and Malaysia. These are the factors that are expected to drive the botulinum toxin sector in the region. 

Some of the prominent players in the botulinum toxin market include:

  • Ipsen Group
  • Allergen, Inc.
  • Metabiologics
  • Merz Pharma
  • US Worldmeds
  • Evolus
  • Galderma
  • Lanzhou Institute of Biological Products

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global botulinum toxin market.

Product Type

  • Type A
    • Botox
    • Dysport
    • Xeomin
    • Others
  • Type B

Application

  • Therapeutic
    • Chronic Migraine
    • Overactive Bladder
    • Cervical Dystonia
    • Spasticity
    • Others
  • Aesthetic
    • Glabellar Lines
    • Crow’s Feet
    • Forehead Lines
    • Others

End-use

  • Hospitals
  • Dermatology Clinics
  • Cosmetic Centers and Medspas

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global botulinum toxin market size was exhibited at USD 11.30 billion in 2023 and is projected to hit around USD 29.04 billion by 2033.

The global botulinum toxin market is expected to grow at a compound annual growth rate of 9.9% from 2024 to 2033 to reach USD 29.04 billion by 2033.

Some key players operating in the botulinum toxin market include Allergan, Inc.; Ipsen Group; Merz Pharma GmbH & Co. KGaA; Medytox,Inc.; US Worldmed,LLC; Lanzhou Institute of Biological Products Co.Ltd. and Revance Therapeutics, Inc.

Chapter 1 Botulinum Toxin Market: Methodology And Scope

1.1 Market Segmentation & Scope

1.1.1 Product Type

1.1.2 Application

1.1.3 End-Use

1.1.4 Regional Scope

1.1.5 Estimates And Forecast Timeline

1.2 Research Methodology

1.3 Information Procurement

1.3.1 Purchased Database

1.3.2 Internal Database

1.3.3 Secondary Sources

1.3.4 Primary Research

1.3.5 Details Of Primary Research

1.4 Information Or Data Analysis

1.4.1 Data Analysis Models

1.5 Market Formulation & Validation

1.6 Model Details

1.6.1 Commodity Flow Analysis (Model 1)

1.7 List Of Secondary Sources

1.8 List Of Primary Sources

1.9 List Of Abbreviations

1.10 Objectives

1.10.1 Objective - 1

1.10.2 Objective - 2

1.10.3 Objective - 3

Chapter 2 Botulinum Toxin Market: Executive Summary

2.1 Market Snapshot

2.2 Segment Snapshot

2.3 Competitive Landscape Snapshot

Chapter 3 Botulinum Toxin Market: Variables, Trends, & Scope

3.1 Market Segmentation And Scope

3.2 Market Dynamics

3.2.1 Market Driver Analysis

3.2.2.1 Increasing Number Of Patients Having Neurological Disorders

3.2.2.2 Rising Preference For Non-Invasive Or Minimally Invasive Procedures

3.2.2.3 Increasing Concern Regarding Aesthetic Appearance In 40-54 Age Group Has Increased The Adoption Rate

3.2.2 Market Restraint Analysis

3.2.2.1 High Cost Of Cosmetic Procedure

3.3 Botulinum Toxin: Market Analysis Tools

3.3.1 Industry Analysis - Porter’s

3.3.2 Pestel Analysis

3.4 COVID-19 Impact Analysis

Chapter 4 Botulinum Toxin Market: Product Type Segment Analysis

4.1 Botulinum Toxin: Product Type Market Share Analysis, 2024 & 2033

4.2 Type A

4.2.1 Type A Market Estimates And Forecasts, 2021 - 2033

4.2.1.1 Botox

4.2.1.2 Dysport

4.2.1.3 Xeomin

4.2.1.4 Others

4.2.2 Type B

4.2.2.1 Type B Market Estimates And Forecasts, 2021 - 2033

Chapter 5 Botulinum Toxin Market: Application Segment Analysis

5.1 Botulinum Toxin: Application Market Share Analysis, 2024 & 2033

5.2 Therapeutic

5.2.1 Therapeutic Market Estimates And Forecasts, 2021 - 2033

5.2.1.1 Chronic Migraine

5.2.1.2 Overactive Bladder

5.2.1.3 Cervical Dystonia

5.2.1.4 Spasticity

5.2.1.5 Others

5.3 Aesthetic

5.3.1 Aesthetic Market Estimates And Forecasts, 2021 - 2033

5.3.1.1 Glabellar Lines

5.3.1.2 Crow's Feet

5.3.1.3 Forehead Lines

5.3.1.4 Others

Chapter 6 Botulinum Toxin Market: End-Use Segment Analysis

6.1 Botulinum Toxin: End-Use Market Share Analysis, 2024 & 2033

6.2 Hospitals

6.2.1 Hospitals Market Estimates And Forecasts, 2021 - 2033

6.3 Dermatology Clinics

6.3.1 Dermatology Clinics Market Estimates And Forecasts, 2021 - 2033

6.4 Spas And Cosmetic Centers

6.4.1 Spas And Cosmetic Centers Market Estimates And Forecasts, 2021 - 2033

Chapter 7 Botulinum Toxin Market: Regional Analysis

7.1 Botulinum Toxin: Regional Market Share Analysis, 2024 & 2033

7.2 North America

7.2.1 North America Botulinum Toxin Market, 2021 - 2033

7.2.2 U.S.

7.2.2.1 Key Country Dynamics

7.2.2.2 U.S. Botulinum Toxin Market, 2021 - 2033

7.2.3 Canada

7.2.3.1 Key Country Dynamics

7.2.3.2 Canada Botulinum Toxin Market, 2021 - 2033

7.3 Europe

7.3.1 Europe Botulinum Toxin Market, 2021 - 2033

7.3.2 UK

7.3.2.1 Key Country Dynamics

7.3.2.2 UK Botulinum Toxin Market, 2021 - 2033

7.3.3 Germany

7.3.3.1 Key Country Dynamics

7.3.3.2 Germany Botulinum Toxin Market, 2021 - 2033

7.3.4 France

7.3.4.1 Key Country Dynamics

7.3.4.2 France Botulinum Toxin Market, 2021 - 2033

7.3.5 Italy

7.3.5.1 Key Country Dynamics

7.3.5.2 Italy Botulinum Toxin Market, 2021 - 2033

7.3.6 Spain

7.3.6.1 Key Country Dynamics

7.3.6.2 Spain Botulinum Toxin Market, 2021 - 2033

7.3.7 Denmark

7.3.7.1 Key Country Dynamics

7.3.7.2 Denmark Botulinum Toxin Market, 2021 - 2033

7.3.8 Sweden

7.3.8.1 Key Country Dynamics

7.3.8.2 Sweden Botulinum Toxin Market, 2021 - 2033

7.3.9 Norway

7.3.9.1 Key Country Dynamics

7.3.9.2 Norway Botulinum Toxin Market, 2021 - 2033

7.4 Asia Pacific

7.4.1 Asia Pacific Botulinum Toxin Market, 2021 - 2033

7.4.2 China

7.4.2.1 Key Country Dynamics

7.4.2.2 China Botulinum Toxin Market, 2021 - 2033

7.4.3 India

7.4.3.1 Key Country Dynamics

7.4.3.2 India Botulinum Toxin Market, 2021 - 2033

7.4.4 Japan

7.4.4.1 Key Country Dynamics

7.4.4.2 Japan Botulinum Toxin Market, 2021 - 2033

7.4.5 South Korea

7.4.5.1 Key Country Dynamics

7.4.5.2 South Korea Botulinum Toxin Market, 2021 - 2033

7.4.6 Australia

7.4.6.1 Key Country Dynamics

7.4.6.2 Australia Botulinum Toxin Market, 2021 - 2033

7.4.7 Thailand

7.4.7.1 Key Country Dynamics

7.4.7.2 Thailand Botulinum Toxin Market, 2021 - 2033

7.5 Latin America

7.5.1 Latin America Botulinum Toxin Market, 2021 - 2033

7.5.2 Brazil

7.5.2.1 Key Country Dynamics

7.5.2.2 Brazil Botulinum Toxin Market, 2021 - 2033

7.5.3 Mexico

7.5.3.1 Key Country Dynamics

7.5.3.2 Mexico Botulinum Toxin Market, 2021 - 2033

7.5.4 Argentina

7.6.4.1 Key Country Dynamics

7.6.4.2 Argentina Botulinum Toxin Market, 2021 - 2033

7.6 MEA

7.6.1 MEA Botulinum Toxin Market, 2021 - 2033

7.6.2 South Africa

7.6.2.1 Key Country Dynamics

7.6.2.2 South Africa Botulinum Toxin Market, 2021 - 2033

7.6.3 Saudi Arabia

7.6.3.1 Key Country Dynamics

7.6.3.2 Saudi Arabia Botulinum Toxin Market, 2021 - 2033

7.6.4 UAE

7.6.4.1 Key Country Dynamics

7.6.4.2 UAE Botulinum Toxin Market, 2021 - 2033

7.6.5 Kuwait

7.6.5.1 Key Country Dynamics

7.6.5.2 Kuwait Botulinum Toxin Market, 2021 - 2033

Chapter 8 Company Profiles

8.1. Recent Developments & Impact Analysis, By Key Market Participants

8.2. Botulinum Toxin- Market Share Analysis

8.3. Ipsen Group

8.3.1 Company Overview

8.3.2 Financial Performance

8.3.3 Product Benchmarking

8.3.4 Strategic Initiatives

8.4. Allergen Inc.

8.4.1 Company Overview

8.4.2 Financial Performance

8.4.3 Product Benchmarking

8.4.4 Strategic Initiatives

8.5 Medy-Tox, Inc.

8.5.1 Company Overview

8.5.2 Financial Performance

8.5.3 Product Benchmarking

8.5.4 Strategic Initiatives

8.6 Metabiologics

8.6.1 Company Overview

8.6.2 Financial Performance

8.6.3 Strategic Initiatives

8.7 Merz Pharma

8.7.1 Company Overview

8.7.2 Financial Performance

8.7.3 Product Benchmarking

8.7.4 Strategic Initiatives

8.8 US Worldmeds

8.8.1 Company Overview

8.8.2 Financial Performance

8.8.3 Product Benchmarking

8.8.4 Strategic Initiatives

8.9 Evolus

8.9.1 Company Overview

8.9.2 Financial Performance

8.9.3 Product Benchmarking

8.9.4 Strategic Initiatives

8.10 Galderma

8.10.1 Company Overview

8.10.2 Financial Performance

8.10.3 Product Benchmarking

8.10.4 Strategic Initiatives

8.11 Lanzhou Institute Of Biological Products

8.11.1 Company Overview

8.11.2 Financial Performance

8.11.3 Product Benchmarking

 

8.11.4 Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers